Zatolmilast Clinical Program
About Fragile X Syndrome (FXS)
About Tetra Therapeutics
About Shionogi
Forward-Looking Statements
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
U.S. Media Contact: ShionogiCommunications@shionogi.com
References
1. Berry-Kravis, E.M., Harnett, M.D., Reines, S.A. et al. Inhibition of hosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nat Med 27, 862–870 (2021). https://doi.org/10.1038/s41591-021-01321-w.
2. Cleveland Clinic. (2021, May 18). Fragile X Syndrome: Diagnosis, Symptoms & Treatment. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/5476-fragile-x-syndrome
3. Centers for Disease Control and Prevention. What is Fragile X Syndrome? CDC. https://www.cdc.gov/ncbddd/fxs/facts.html
4. Ciaccio, C., Fontana, L., Milani, D., et al. Fragile X syndrome: A review of clinical and molecular diagnoses. Italian Journal of Pediatrics. (2017, April 19). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395755/